MGB Biopharma

Stock Exchange: Privately held Ticker: - HQ: Bellshill, Scotland, UK Employees: 10 Signatory to Davos Decl: Yes Signatory to Industry Roadmap: No
Performance by research area
How MGB Biopharma was evaluated
1 2.1 2.2 2.3 3 4
R&D A
1 2 3
M&P B
1 2 3 4 5 6 7
AA&S C
Applicable indicator Not applicable

Performance

MGB Biopharma is a biopharmaceutical company, selected for having a pipeline that targets priority pathogens. It was evaluated in the area of Research & Development only. The company performs well compared to other biopharmaceutical companies in scope. MGB Biopharma has four projects in its antimicrobial R&D pipeline, all targeting priority pathogens, including one novel antibiotic candidate. The company engages in numerous public-private partnerships and agreements with various organisations to develop its antibiotic candidates.

Operations

MGB Biopharma, founded in 2010, is a biopharmaceutical company focussing on a new class of anti-infectives, the DNA Minor Groove Binders (MGBs), which interact with microbial cell DNA and interfere with its replication. MGBs were originally developed at the University of Strathclyde in Glasgow, which licensed the technology to MGB Biopharma, granting the company exclusive global rights in all fields except cancer. The company’s most advanced drug candidate, MGB-BP-3, is active against gram-positive bacteria and has recently completed a Phase I clinical safety study in the oral treatment of C. difficile infection. The compound is an analogue of the naturally occurring antibiotic (and antiviral) distamycin. MGB Biopharma has plans to extend the therapeutic indications of this compound and is currently developing MGBs that are active against viruses, fungi and parasites. The University of Strathclyde remains a close partner of the company in the development of its MGB pipeline. MGB Biopharma has no products on the market. In 2017, the company closed a USD 1 million financing round to fund the development and production of MGB-BP-3 for a Phase II clinical study in C. difficile infection. The financing round was led by Archangel Investors Limited and included contributions from TRI Capital Ltd, Barwell plc and Scottish Investment Bank.

Antimicrobial Portfolio

MGB Biopharma does not have any products on the market.

Opportunities

Plan ahead for access and stewardship during R&D. Plan ahead for access and stewardship during R&D. MGB Biopharma has one antibiotic candidate (MGB-BP-3) in clinical development, currently in Phase I. MGB Biopharma is encouraged to implement access and stewardship plans for this candidate as it moves into Phase II clinical development.

A. Research & Development

Indicators scored on
  • 1
  • 2.1
  • 2.2
  • 2.3
  • 3
  • 4
Antimicrobial pipeline
4 projects, 4 target priority pathogens

A.2.1-2.2 One novel antibiotic in the clinical pipeline. 

Biopharmaceutical companies in scope were selected based on their pipelines that target priority bacteria. MGB Biopharma has four projects in its antimicrobial R&D pipeline, all targeting priority pathogens. MGB Biopharma is currently developing its MGB-BP-3 antibiotic for the treatment of C. difficile infections. MGB-BP-3’s antimicrobial activity is based on a new mode of action, namely its activity as a DNA Minor Groove Binder (MGB). Despite being in development for treatment of C. difficile infections, MGB-BP-3 is also active against other gram-positive bacteria, such as methicillin-resistant S. aureus (MRSA), vancomycin-resistant Enterococcus (VRE) and Streptococci. The company is also developing intravenous and topical formulations of the compound in preclinical stages, and has discovery platforms for gram-negative bacteria and fungi.

A.3 All R&D projects being developed with public partner. 

MGB Biopharma is developing all three R&D projects in its priority pathogen pipeline in collaboration with the University of Strathclyde.

A.4 No R&D candidates in late-stage development. 

MGB Biopharma is not eligible for this indicator as it does not have any R&D candidates in late-stage development.

Pipeline targeting priority pathogens

Enlarge

B. Manufacturing & Production

As a biopharmaceutical company with no products on the market, MGB Biopharma was not eligible for this Research Area.

C. Appropriate Access & Stewardship

As a biopharmaceutical company with no products on the market, MGB Biopharma was not eligible for this Research Area.



Got a question?

Learn more

View our detailed overview of each company’s performance